Risk of diabetic ketoacidosis with sodium-glucose cotransporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A nationwide cohort study
Sage Open Chronic Disease · 2026-02 · 17
DOI: 10.1177/27558428261421697 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Sage Open Chronic Disease, online erschienen am 19.03.2026. Verfasst von Hsiao-Yun Yeh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education, Taipei Veterans General Hospital, Taiwan. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science and Technology Council.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have significantly improved glycemic control and reduced cardiovascular and renal risks in type 2 diabetes mellitus (T2DM). However, diabetic ketoacidosis (DKA), though rare, remains a serious safety concern. While previous studies have established an elevated DKA risk with SGLT2is, real-world evidence in Asian populations remains limited.
Objectives
This study evaluated the real-world risk of DKA associated with SGLT2i use compared to dipeptidyl peptidase-4 inhibitors (DPP4is) in patients with T2DM in Taiwan.
Design
A nationwide population-based cohort study using Taiwan’s National Health Insurance Research Database.
Methods
This study included over 700,000 patients with T2DM who initiated SGLT2is or DPP4is between 2016 and 2020. A prevalent new-user design was applied, and inverse probability treatment weighting was used to balance baseline characteristics. DKA cases were identified using validated diagnostic codes from hospital admissions and emergency visits.
Results
The incidence of DKA was higher in SGLT2i users (0.34 per 1000 person-years (PY)) than in DPP4i users (0.19 per 1000 PY), with an adjusted hazard ratio of 2.04 (95% CI: 1.64–2.54). Subgroup analyses revealed a consistently elevated DKA risk, particularly among men, older adults, and patients with advanced diabetes complications. Sensitivity analyses, including an E -value of 3.72, suggested minimal impact from unmeasured confounders.
Conclusion
SGLT2i use was associated with a twofold increased DKA risk compared to DPP4is in this Asian cohort. Although the absolute incidence was low, targeted monitoring is warranted in high-risk populations. The lower DKA incidence observed in Taiwan compared to Western studies suggests potential regional influences, necessitating further investigation. These findings contribute to the understanding of SGLT2i safety in Asian populations and inform clinical risk management strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Education, Taipei Veterans General Hospital, Taiwan.
- Department of Family Medicine, Taipei Veterans General Hospital, Taiwan.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Division of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taiwan.
ORCID-Profile: Hsiao-Yun Yeh
Förderung
- National Science and Technology Council
Zitieren
APA
Yeh, H. Y., Lu, H. F., Lin, L. Y., & Chien, L. N. (2026). Risk of diabetic ketoacidosis with sodium-glucose cotransporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A nationwide cohort study. Sage Open Chronic Disease, 17. https://doi.org/10.1177/27558428261421697
Vancouver
Yeh HY, Lu HF, Lin LY, Chien LN. Risk of diabetic ketoacidosis with sodium-glucose cotransporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A nationwide cohort study. Sage Open Chronic Disease. 2026;17. doi:10.1177/27558428261421697
BibTeX
@article{Yeh2026,
author = {Yeh, Hsiao-Yun and Lu, Hong-Fu and Lin, Liang-Yu and Chien, Li-Nien},
title = {Risk of diabetic ketoacidosis with sodium-glucose cotransporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A nationwide cohort study},
journal = {Sage Open Chronic Disease},
year = {2026},
volume = {17},
doi = {10.1177/27558428261421697}
}
EUVIMED